Aegerion’s Jeffrey Bloss Joins Tarveda as Chief Medical Officer

Xconomy Boston — 

Jeffrey Bloss has been appointed chief medical officer of Tarveda Therapeutics. Bloss comes to Watertown, MA-based Tarveda from Aegerion Pharmaceuticals, where he was chief medical officer and senior vice president, medical affairs. His experience includes senior roles at Astellas Pharma (OTCMKTS: ALPMY), GlaxoSmithKline (NYSE: GSK), Genentech, and Eli Lilly (NYSE: LLY). Last year, Tarveda raised $30 million to finance clinical trials for its experimental cancer drugs.